Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14012
Country/Region: Kenya
Year: 2016
Main Partner: Moi Teaching and Referral Hospital
Main Partner Program: NA
Organizational Type: Parastatal
Funding Agency: USAID
Total Funding: $15,501,035 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,918,797
Care: Orphans and Vulnerable Children (HKID) $933,680
Care: TB/HIV (HVTB) $954,436
Care: Pediatric Care and Support (PDCS) $480,408
Laboratory Infrastructure (HLAB) $300,000
Strategic Information (HVSI) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,558,786
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,662,898
Treatment: Adult Treatment (HTXS) $6,081,752
Treatment: Pediatric Treatment (PDTX) $610,278
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 70
HTS_TST Age/sex: 1-9 2017 1,745
HTS_TST Age/sex: 10-14 Female 2017 929
HTS_TST Age/sex: 10-14 Male 2017 815
HTS_TST Age/sex: 15-19 Female 2017 336
HTS_TST Age/sex: 15-19 Male 2017 350
HTS_TST Age/sex: 20-24 Female 2017 419
HTS_TST Age/sex: 20-24 Male 2017 153
HTS_TST Age/sex: 25-49 Female 2017 10,973
HTS_TST Age/sex: 25-49 Male 2017 5,218
HTS_TST Age/sex: 50+ Female 2017 2,922
HTS_TST Age/sex: 50+ Male 2017 2,884
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,368
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 78,519
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,496
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 79,586
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 7,215
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 357,186
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 5,207
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 186,242
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 15,286
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 702,334
HTS_TST Service Delivery Point (Facility): Inpatient 2017 981
HTS_TST Service Delivery Point (Facility): Inpatient 2017 35,193
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 3
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2,576
HTS_TST Service Delivery Point (Facility): Other PITC 2017 91,582
HTS_TST Service Delivery Point (Facility): Outpatient 2017 7,765
HTS_TST Service Delivery Point (Facility): Outpatient 2017 305,094
HTS_TST Service Delivery Point (Facility): Pediatric 2017 105
HTS_TST Service Delivery Point (Facility): Pediatric 2017 2,920
HTS_TST Service Delivery Point (Facility): PMTCT 2017 124,943
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 19
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 774
HTS_TST Service Delivery Point (Facility): VCT 2017 3,840
HTS_TST Service Delivery Point (Facility): VCT 2017 141,527
HTS_TST Sum of Age/Sex disaggregates 2017 24,999
HTS_TST Sum of Aggregated Age/Sex <15 2017 2,864
HTS_TST Sum of Aggregated Age/Sex <15 2017 158,105
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 12,422
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 543,428
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 15,286
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 701,533
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 17
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 15
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 11
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 12
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 13
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 5
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 357
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 172
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 97
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 92
HTS_TST_POS Test Result by Age: Positive: <1 2017 1
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 32
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 12
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,034
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 8
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 886
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 260
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 7,290
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 153
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,797
OVC_SERV Age/Sex: 18+ Female 2017 1,048
OVC_SERV Age/Sex: 18+ Male 2017 1,074
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 9,451
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 9,647
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 21,220
OVC_SERV Sum of Age/Sex disaggregates 2017 2,122
PMTCT_ART Already on ART at beginning of current pregnancy 2017 2,305
PMTCT_ART New on ART 2017 2,109
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 127,474
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 22
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,015
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 9
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,075
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 113
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 54
PMTCT_EID Sum of Infant Age disaggregates 2017 31
PMTCT_EID Sum of Infant Age disaggregates 2017 4,090
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 11
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 230
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 230
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 233
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 115
PMTCT_STAT By: Known positives at entry 2017 2,206
PMTCT_STAT By: Number of new positives identified 2017 1,812
PMTCT_STAT Number of new ANC and L&D clients 2017 134,183
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 127,474
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 1
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 31
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 31
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 31
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 16
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 1
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 10
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 10
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 10
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 5
PMTCT_STAT Sum of Positives Status disaggregates 2017 4,018
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 12
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 243
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 243
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 242
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 122
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 110
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,128
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 93
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,094
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 2,608
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 2,425
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 48
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 48
TB_SCREENDX Screen Result: Screened Positive for TB 2017 240
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 43,564
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 35,125
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 4,851
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 3,917
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 87,457
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 202
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,294
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 317
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,578
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 6,391
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 6,614
TX_CURR Age/Sex: <1 2017 23
TX_CURR Age/Sex: <1-9 2017 584
TX_CURR Age/Sex: 10-14 Female 2017 312
TX_CURR Age/Sex: 10-14 Male 2017 273
TX_CURR Age/Sex: 15-19 Female 2017 128
TX_CURR Age/Sex: 15-19 Male 2017 133
TX_CURR Age/Sex: 20-24 Female 2017 161
TX_CURR Age/Sex: 20-24 Male 2017 60
TX_CURR Age/Sex: 25-49 Female 2017 4,169
TX_CURR Age/Sex: 25-49 Male 2017 1,988
TX_CURR Age/Sex: 50+ Female 2017 1,115
TX_CURR Age/Sex: 50+ Male 2017 1,096
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,887
TX_CURR Aggregated Age/Sex: <15 Male 2017 3,952
TX_CURR Aggregated Age/Sex: 15+ Female 2017 43,809
TX_CURR Aggregated Age/Sex: 15+ Male 2017 35,385
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 88,033
TX_CURR Sum of age/sex disaggregates 2017 261
TX_CURR Sum of Aggregated Age/Sex <15 2017 8,839
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 79,194
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 88,033
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 985
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 856
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 8,778
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 7,232
TX_NEW By Age/Sex: <1 2017 4
TX_NEW By Age/Sex: 1-9 2017 119
TX_NEW By Age/Sex: 10-14 Female 2017 64
TX_NEW By Age/Sex: 10-14 Male 2017 57
TX_NEW By Age/Sex: 15-19 Female 2017 26
TX_NEW By Age/Sex: 15-19 Male 2017 27
TX_NEW By Age/Sex: 20-24 Female 2017 32
TX_NEW By Age/Sex: 20-24 Male 2017 11
TX_NEW By Age/Sex: 25-49 Female 2017 857
TX_NEW By Age/Sex: 25-49 Male 2017 409
TX_NEW By Age/Sex: 50+ Female 2017 228
TX_NEW By Age/Sex: 50+ Male 2017 225
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 17,807
TX_NEW Sum of Age/Sex disaggregates 2017 1,936
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 17,851
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 88,035
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 79,231
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 4,404
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 3,547
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 39,475
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 31,805
TX_PVLS Numerator: Indication: Routine 2017 68,294
TX_PVLS Numerator: Indication: Targeted 2017 11,338
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 4,893
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,949
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 43,801
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 35,392
TX_PVLS_den Denominator: Indication: Routine 2017 76,307
TX_PVLS_den Denominator: Indication: Targeted 2017 12,172
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 107
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 57
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 51
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 24
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 25
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 10
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 772
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 366
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 206
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 200
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 812
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 663
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7,224
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,923
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 14,622
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 17,805
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 121
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 64
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 61
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 26
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 28
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 32
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 12
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 855
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 397
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 228
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 231
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 987
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 819
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8,764
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,235
Cross Cutting Budget Categories and Known Amounts Total: $73,448
Gender: Gender Based Violence (GBV) $73,448
GBV Prevention